Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AB Science

Criteria

Key Inclusion Criteria:

• Male or non-pregnant female with: A. Symptomatic ambulatory male or non-pregnant female adult ≥ 18 years of age at time of enrolment with mild COVID-19 with score 2 or 3 of the 10-score WHO clinical progression scale OR B. Hospitalized male or non-pregnant female adult ≥ 18 years of age at time of enrolment with COVID-19 with score 4 or 5 of the 10-score WHO clinical progression scale.

• Symptoms consistent with COVID-19, as determined by investigator, with onset ≤5 days before randomization

• Positive test for COVID-19 ≤72 hours prior to randomization

• Negative test for the IgG anti-SARS-CoV-2

Key Exclusion Criteria:

• Any use of anti-viral medications up to 7 days before participating in the study

• Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) any time before participating in the study

• Receipt of last recommended dose of a SARS-CoV-2 vaccine up to 30 days before participating in the study

• Receipt of a monoclonal antibodies up to 30 days before participating in the study.

Other protocol-defined inclusion/exclusion criteria may apply